RxDoctor Payments Data

Cody Christensen, DO

Urology · Rock Springs, WYNPI 1962765586

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Coloplast at 31.2% of the total. 2025 is the largest year on record at $1,571, 4.5 times the $353 reported in 2019.

$3,636in general payments, 2019–2025

Across 68 payments — averaging $53.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$1K
  • Boston Scientific$615
  • Neotract Inc.$447
  • Procept Biorobotics Corporation$403
  • Astellas Pharma US Inc$297
  • Teleflex LLC$210
  • plus $529 from 14 others

What the payments were for

  • Travel & lodging$1,65145%
  • Food & beverage$1,71647%
  • Education$2687%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$180,842
Medicare patients
636
Services billed
3,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron75$50,362
Tamsulosin Hcl513$9,628
Silodosin25$3,527
Methenamine Hippurate65$3,474
Finasteride127$2,206
Trospium Chloride37$2,049
Estradiol21$1,070
Potassium Citrate ErPotassium Citrate27$1,051
Gentamicin Sulfate62$1,038
Testosterone Cypionate31$832
Solifenacin Succinate38$778
Alfuzosin Hcl ErAlfuzosin Hcl33$724
Cephalexin93$513
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$441
Dutasteride14$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$297$50,36275 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other urology in Rock Springs

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →